Papers

Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study

David M Coulter, head ^a, Andrew Bate, programme leader, signal research methodology ^b, Ronald H B Meyboom, medical adviser ^b, Marie Lindquist, head of research and development ^b, I Ralph Edwards, director ^b. 

^a Centre for Adverse Reactions Monitoring and Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand, ^b Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, S-75320 Uppsala, Sweden

Correspondence to: I R Edwards ralph.edwards{at}who-umc.org

	Abstract

Top Abstract Introduction Methods Results Discussion References

Objectives: To examine the relation between antipsychotic drugs and myocarditis and cardiomyopathy.
Design: Data mining using bayesian statistics implemented in a neural network architecture.
Setting: International database on adverse drug reactions run by the World Health Organization programme for international drug monitoring.
Main outcome measures: Reports mentioning antipsychotic drugs, cardiomyopathy, or myocarditis.
Results: A strong signal existed for an association between clozapine and cardiomyopathy and myocarditis. An association was also seen with other antipsychotics as a group. The association was based on sufficient cases with adequate documentation and apparent lack of confounding to constitute a signal. Associations between myocarditis or cardiomyopathy and lithium, chlorpromazine, fluphenazine, haloperidol, and risperidone need further investigation.
Conclusions: Some antipsychotic drugs seem to be linked to cardiomyopathy and myocarditis. The study shows the potential of bayesian neural networks in analysing data on drug safety.

	Introduction

Top Abstract Introduction Methods Results Discussion References

The antipsychotic drug clozapine has been reported to cause myocarditis or cardiomyopathy. ^{1 2} other drugs in the same therapeutic class may share similar toxicity. Data mining of a large database of suspected adverse reactions can find such new signals. As part of the World Health Organization's programme for international drug monitoring, national pharmacovigilance centres in 60 countries report adverse reactions to a central database maintained by the Uppsala Monitoring Centre in Sweden.³

To analyse this large database an approach using bayesian statistics implemented in a neural network architecture has been developed. The approach is able to look for new adverse reactions from combinations of drugs and also to identify previously unknown patterns, such as risk factors for adverse events with specific drugsfor example, patient age, underlying diseases, and drug interactions. We used the bayesian approach to look for cardiac effects related to antipsychotic drugs in the WHO database of adverse reactions.

	Methods

Top Abstract Introduction Methods Results Discussion References

We used the bayesian confidence propagation network, which implements bayesian statistics in a neural network architecture, in the WHO database. The network was used to test reports of clozapine and all other antipsychotic drugs suspected of causing myocarditis or cardiomyopathy against a background of all reports in the database. We calculated the strength of dependency between a drug (or drug group) and adverse reaction using a logarithmic measure of disproportionality called the information component.⁴ An association between the drug and the reaction was considered significant if the information component minus 2 standard deviations was positive. The value of the information component is based on the number of case reports for drug(s) "x" (Cx); the number of case reports of adverse reaction(s) "y" (Cy); the number of reports of the specific combination (Cxy); and the total number of reports (C). Further details of the methods are available on the BMJ 's website.

	Results

Top Abstract Introduction Methods Results Discussion References

Myocarditis and cardiomyopathy were reported rarely as suspected adverse drug reactions, accounting for less than 0.1% (2121) of almost 2.5 million reports. The table shows the antipsychotic drugs reported to have caused either myocarditis or cardiomyopathy on two or more occasions. Clozapine has a much higher information component than other antipsychotics together and than the general background database. Most reports predated recent publicity about clozapine. The statistical associations of clozapine with myocarditis and cardiomyopathy individually were also significant. The group of other antipsychotics drugs was significantly associated with myocarditis and cardiomyopathy together (table) and individually compared with the general database, although these associations were much weaker than for clozapine.

Chlorpromazine, lithium, and fluphenazine were significantly associated with myocarditis and cardiomyopathy. The 16 cases with risperidone were not more than expected given the high overall reporting of the drug in the database. Chlorpromazine was also significantly associated with myocarditis and cardiomyopathy separately. Lithium, fluphenazine, and risperidone were significantly associated with cardiomyopathy but not myocarditis. In contrast, haloperidol was associated with myocarditis but not cardiomyopathy.

	Discussion

Top Abstract Introduction Methods Results Discussion References

Our analysis suggests that antipsychotic drugs other than clozapine may be associated with myocarditis and cardiomyopathy. The findings may have three explanations. The conditions for which antipsychotics are used could be risk factors for myocarditis and cardiomyopathy; the antipsychotic drug could be an innocent bystander; or there may be a causal association. Despite patients taking clozapine being intensively monitored for agranulocytosis, the former two are unlikely explanations for the strong relation between clozapine and myocarditis and cardiomyopathy.⁵ The association with clozapine cannot be explained by coprescribed drugs. In some of the cases in the other antipsychotics group the patient was also taking clozapine or non-antipsychotic drugs known to cause myocarditis or cardiomyopathy. However, standardised clinical evaluation⁶ shows that there were sufficient cases with adequate documentation and apparent lack of confounding to constitute a signal for cardiomyopathy or myocarditis in the other antipsychotics identified above.

Choice of methods
Our results were obtained by a data mining approach. A concern had been raised about myocarditis with clozapine. We then examined the association between the group of antipsychotics with myocarditis or cardiomyopathy. Having discovered a quantitative association between the antipsychotics group and cardiomyopathy and myocarditis, we investigated individual antipsychotic drugs and then performed a case by case analysis. Our study shows that data mining can be used successfully to detect signals of adverse reactions in the WHO database.

Implications
The summaries of case histories in the database do not allow us to draw definite conclusions about the likelihood of the possible causes of the associations we observed between antipsychotic drugs and myocarditis and cardiomyopathy. Adverse drug reactions are greatly underreported worldwide. Further study is needed to determine if antipsychotics other than clozapine cause myocarditis or cardiomyopathy, particularly lithium, chlorpromazine, fluphenazine, haloperidol, and risperidone, and to consider the comparative risks and effectiveness of antipsychotics. This is especially important given the recent finding that older and newer drugs have similar efficacy.⁹ Antipsychotic drugs should also be considered in unexplained sudden deaths in psychotic patients.

	Acknowledgments

We thank the national centres that contribute data to the WHO international drug monitoring programme. The opinions and conclusions, however, are not necessarily those of the various national centres or of the WHO. Roland Orre was central in developing the bayesian confidence propagation neural network as a routine tool for signal detection in the WHO database of drug adverse reactions.

Contributors: DMC suggested the study and made a provisional investigation of the data, AB and IRE planned and designed the study; AB carried out the study; and IRE, AB, and ML evaluated the results. RHBM drafted the first report of the study, AB and IRE wrote the paper, and all authors contributed to modifying the manuscript and the final editing of the paper. IRE is the guarantor.

	Footnotes

Funding: None.

Competing interests: None declared.

Details of the methods are available on the BMJ's website

	References

Top Abstract Introduction Methods Results Discussion References

1.	Jensen VE, Gotzsche O. Allergic myocarditis in clozapine treatment. Ugeskrift for Laeger 1994; 156: 4151-4152[Medline].
2.	Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-1845[CrossRef][Medline].
3.	Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Safety 1998; 19: 1-10[CrossRef][Medline].
4.	Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-321[Medline].
5.	Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the clozaril national registry. J Clin Psychiatry 1998; 59(suppl 3): 3-7.
6.	Edwards IR, Lindquist M, Wiholm B-E, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156-158[Medline].
7.	Hand DJ. Statistics and data mining: intersecting disciplines. SIGKDD Explorations 1999; 1: 16-19.
8.	Edwards IR. Adverse drug reactions: finding the needle in the haystack. BMJ 1997; 315: 500[Free Full Text].
9.	Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376[Abstract/Free Full Text].

(Accepted 20 February 2001)